Patrick Verheyen, head of innovation in London for Johnson & Johnson, speaks during an interview in London, U.K., on Thursday, July 18, 2013. Second-quarter sales rose 8.5 percent to $17.9 billion, helped by demand for the company's newer pharmaceutical offerings including the blood thinner Xarelto and the prostate cancer medicine Zytiga. Photographer: Simon Dawson/Bloomberg via Getty Images
A logo sits on a wall inside Johnson & Johnson's innovation centre in London, U.K., on Thursday, July 18, 2013. Second-quarter sales rose 8.5 percent to $17.9 billion, helped by demand for the company's newer pharmaceutical offerings including the blood thinner Xarelto and the prostate cancer medicine Zytiga. Photographer: Simon Dawson/Bloomberg via Getty Images
Prostate Gland Adenocarcinoma
Prostate Cancer Cross Section
